Wet age-related macular degeneration combined with branch retinal vein occlusion

Purpose: To study the safety and efficacy of intravitreal Ziv-Aflibercept vs. Bevacizumab for the management of edema caused by different retinal pathologies. Study Design: Comparative interventional study. Place and Duration of Study: Lahore General Hospital, Lahore, from July 2018 to June 2019. Material and Methods: Patients with resistant, center involving macular edema due to diabetes, retinal vein occlusion and age related macular degeneration were recruited. Complete ocular examination was performed. All the patients were randomly grouped into two i.e. IVZ (intravitreal Ziv-Aflibercept) and IVB (intravitreal bevacizumab). Each eye underwent intravitreal injection of 0.05 ml of fresh filtered ziv-aflibercept (1.25 mg) or 0.05 ml of fresh filtered Bevacizumab. Outcome was measured in terms of variation in central macular thickness (CMT) and also best corrected visual acuity (BCVA) at 3 months. Results: Total of 156 eyes of 136 patients completed whole duration of study and were included in the results. The mean baseline CMT was 510 μm (± 94 μm) in the IVB group and 493μm (±102 μm) in the IVZ group (P = 0.94). The mean baseline BCVA (log MAR) was 0.78 (Snellen's equivalent 6/36) in the IVZ and 0.70 (Snellen's equivalent 6/30) in the IVB group (P = 0.78). Central macular thickness was significantly reduced at 1st, 2nd and 3rd month in the IVZ group and IVB group (P < 0.001). Conclusion: Intravitreal Ziv-Aflibercept is safe and more effective than Bevacizumab for the treatment of edema caused by diabetes mellitus, retinal vein occlusion and wet age related macular degeneration.

Download Full-text

Frequency of Cataract Surgery after Intravitreal Injection of High-Dosage Triamcinolone Acetonide

European Journal of Ophthalmology ◽

10.1177/112067210501500407 ◽

2005 ◽

Vol 15 (4) ◽

pp. 462-464 ◽

Cited By ~ 35

Author(s):

J.B. Jonas ◽

R. Degenring ◽

U. Vossmerbauemer ◽

B. Kamppeter

Keyword(s):

Cataract Surgery ◽

Macular Degeneration ◽

Macular Edema ◽

Intravitreal Injection ◽

Triamcinolone Acetonide ◽

Branch Retinal Vein Occlusion ◽

Age Related Macular Degeneration ◽

Vein Occlusion ◽

Age Related ◽

Diffuse Diabetic Macular Edema

Purpose To evaluate the frequency of cataract surgery after intravitreal injection of high-dosage triamcinolone acetonide in elderly patients. Methods This clinical interventional case series study included 144 phakic eyes that consecutively received an intravitreal injection of about 20 mg triamcinolone acetonide for diffuse diabetic macular edema (n=42 eyes), exudative age-related macular degeneration (n=98), and branch retinal vein occlusion (n=4). Mean age was 72.3±8.9 years. Mean follow-up was 11.0±6.8 months (median, 8.8 months; range, 3 to 35.5 months). Reinjections were carried out in 12 (8.3%) eyes. Results Cataract surgery was performed in 20 (13.9%) eyes 17.4±9.1 months (median, 12.7 months; range, 8.0 to 35.5 months) after the first intravitreal injection. Out of the 20 eyes undergoing cataract surgery, 19 (95%) eyes had received one intravitreal injection, and 1 (5%) eye had received two previous injections. Conclusions In the elderly population of patients with exudative age-related macular degeneration, diffuse diabetic macular edema, or branch retinal vein occlusion, intravitreal high-dosage injection of triamcinolone acetonide leads to clinically significant cataract with eventual cataract surgery in about 15% to 20% of eyes within about 1 year after the intravitreal injection.

Download Full-text

Injection frequency and costs of Anti-Vegf treatments for Neovascular age-related Macular Degeneration, Retinal Vein Occlusion, and Diabetic Macular Edema

Value in Health ◽

10.1016/j.jval.2015.03.1044 ◽

2015 ◽

Vol 18 (3) ◽

pp. A180

Author(s):

A. Turpcu ◽

K. Wilson ◽

A. Huang ◽

D.M. Smith ◽

H. Varker ◽

...

Keyword(s):

Macular Degeneration ◽

Macular Edema ◽

Retinal Vein Occlusion ◽

Diabetic Macular Edema ◽

Age Related Macular Degeneration ◽

Vein Occlusion ◽

Anti Vegf ◽

Age Related ◽

Injection Frequency

Download Full-text

Oxidative Stress and Inflammation in Retinal Degeneration

Antioxidants ◽

10.3390/antiox10050790 ◽

2021 ◽

Vol 10 (5) ◽

pp. 790

Author(s):

Ravirajsinh Jadeja ◽

Pamela Martin

Keyword(s):

Oxidative Stress ◽

Diabetic Retinopathy ◽

Retinitis Pigmentosa ◽

Macular Degeneration ◽

Retinal Vein Occlusion ◽

Age Related Macular Degeneration ◽

Degenerative Diseases ◽

Vein Occlusion ◽

Age Related ◽

And Oxidative Stress

Inflammation and oxidative stress play prominent roles in the pathogenesis of many degenerative diseases of the retina, such as age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal vein occlusion, and retinitis pigmentosa [1–3]. [...]

Download Full-text

Review of Subthreshold Diode Micropulse Laser Treatment for Retinal Diseases

Current Trends in Ophthalmology ◽

10.18314/ctoy.v1i1.1252 ◽

2018 ◽

Vol 1 (1) ◽

pp. 62-70

Author(s):

Juhn AT ◽

Shyu AP ◽

Benjamin J ◽

Zhang Y

Keyword(s):

Diabetic Retinopathy ◽

Treatment Modality ◽

Branch Retinal Vein Occlusion ◽

Age Related Macular Degeneration ◽

Clinical Settings ◽

Retinal Diseases ◽

Micropulse Laser ◽

Vein Occlusion ◽

Age Related ◽

New Treatment

Subthreshold Diode Micropulse (SDM) laser is a relatively new treatment modality that confers very little to no anatomical risk to the retina. However, its efficacy is still being studied, and the scenario where SDM is most useful is still being elucidated. This paper reviews articles from 1997 to 2017 and reviews the settings, results, and outcomes of SDM in various clinical settings including diabetic macular edema, branch retinal vein occlusion, central serous Chorioretinopathy, proliferative diabetic retinopathy, and age-related macular degeneration.

Download Full-text